COVID-19大流行期间老年急性冠脉综合征患者管理的挑战
本文综述了COVID-19大流行背景下老年急性冠脉综合征(ACS)患者管理面临的挑战与策略。缺血性心脏病(IHD)尤其是ACS是全球主要死因,年龄是ACS不良结局的重要预测因素。COVID-19感染似乎加剧老年心脏病患者的风险,且合并心血管疾病、糖尿病和高血压的老年患者COVID-19感染后死亡风险最高。老年ACS患者最佳管理证据匮乏,缺乏稳健的随机对照试验,需权衡治疗策略的风险与获益,在风险大于获益时可考虑保守或姑息治疗。
要点
- 年龄是ACS不良结局的重要预测因素,COVID-19感染加剧老年心脏病患者风险。
- 合并心血管疾病、糖尿病和高血压的老年患者COVID-19感染后死亡风险最高。
- 老年ACS患者最佳管理证据匮乏,需个体化权衡治疗策略风险与获益。
核心结论
- 老年ACS患者在COVID-19大流行期间的管理面临证据匮乏的挑战,需权衡治疗策略的风险与获益。
- 在风险大于获益的情况下,对老年ACS患者采取保守或姑息治疗可能是合理选择。
- 需要进一步证据阐明有创管理对老年ACS患者是否获益,且应在大流行之外继续临床研究。
研究设计与样本
- 本文为综述,旨在评估COVID-19大流行背景下老年ACS患者管理的挑战与策略。
- 原文未报告系统检索范围。
主要发现
- 缺血性心脏病尤其是ACS(包括ST段抬高型心肌梗死、非ST段抬高型心肌梗死和不稳定型心绞痛)是全球主要死因。
- 年龄是ACS后不良结局的重要预测因素。
- COVID-19感染似乎加剧老年心脏病患者的风险,年龄增长与COVID-19感染后院内死亡几率增加相关。
- 合并心血管疾病(尤其IHD)、糖尿病和高血压的老年患者COVID-19感染后死亡风险最高。
- 老年ACS患者最佳管理证据匮乏,缺乏稳健的随机对照试验。
临床怎么用
- 对老年ACS患者应个体化权衡治疗策略的风险与获益。
- 在风险大于获益时,可考虑保守或姑息治疗。
- 需进一步研究阐明有创管理在老年ACS患者中的获益,并持续开展相关临床研究。
局限性
- 老年ACS患者最佳管理证据匮乏,缺乏稳健的随机对照试验。
- COVID-19相关知识快速演变且诸多未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ischaemic heart disease (IHD), in particular acute coronary syndrome (ACS), comprising ST-elevation myocardial infarction, non-ST-elevation myocardial infarction and unstable angina, is the leading cause of death worldwide. Age is a major predictor of adverse outcome following ACS. COVID-19 infection seems to escalate the risk in older patients with heart disease. Increasing odds of in-hospital death is associated with older age following COVID-19 infection. Importantly, it seems older patients with comorbidities such as cardiovascular disease (CVD), in particular IHD, diabetes and hypertension, are at the highest risk of mortality following COVID-19 infection. The evidence is sparse on the optimal care of older patients with ACS with lack of robust randomised controlled trials. In this setting, with the serious threat imposed by the COVID-19 pandemic in the context of rapidly evolving knowledge with much unknown, it is important to weigh the risks and benefits of treatment strategies offered to older patients. In cases where risks outweigh the benefits, it might not be an unreasonable option to treat such patients with a conservative or a palliative approach. Further evidence to elucidate whether invasive management is beneficial in older patients with ACS is required out-with the COVID-19 pandemic. Though it is hoped that the actual acute phase of COVID-19 infection will be short lived, it is vital that important clinical research is continued, given the long-term benefits of ongoing clinical research for patients with long-term conditions, including CVD. This review aimed to evaluate the challenges and the management strategies in the care of older patients presenting with ACS in the context of the COVID-19 pandemic.
引用
- Rowland B, Kunadian V. Challenges in the management of older patients with acute coronary syndromes in the COVID-19 pandemic. Heart. 2020. PMID: 32444504. doi:10.1136/heartjnl-2020-317011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。